Gastric cancer is a common malignancy with a poor prognosis, and surgical treatment
remains the first-line approach to treatment to provide a cure. Despite advances in surgical …

Human epidermal growth factor receptor 2 (HER2) overexpression is increasingly
recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer …

Objective N6-methyladenosine (m6A) RNA methylation and its associated methyltransferase
METTL3 are involved in tumour initiation and progression via the regulation of RNA function …

Background There currently are no internationally recognised treatment guidelines for
patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in …

PURPOSE The role of maintenance therapy for gastric (GC) or gastroesophageal junction
cancer (GEJC) is unclear. We investigated avelumab (anti–programmed death ligand-1 [PD …

Chemotherapy is the preferred treatment for advanced stage gastric cancer (GC) patients
and chemotherapy resistance is the major obstacle to effective cancer therapy. Increasing …

Gastric cancer is the fifth most common cancer and the third leading cause of cancer death
worldwide, posing a severe threat to human health. Surgical resection remains the most …

Berberine, an isoquinoline alkaloid from Coptidis Rhizoma, has been characterized as a
potential anticancer drug due to its good anti-tumor effects. However, the molecular …

Background Immunotherapy has evolved as a critical option to treat diverse cancers. The
active response to immunotherapy relies on the unique interaction between cancer and the …

Background Gastric cancer is the fifth most common cancer worldwide. In" Western"
countries, most people are either diagnosed at an advanced stage, or develop a relapse …